CERS logo

Cerus Corporation (CERS)

$2.02

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CERS

Market cap

$407947452

EPS

-0.03

P/E ratio

--

Price to sales

2.03

Dividend yield

--

Beta

1.841018

Price on CERS

Previous close

$2.13

Today's open

$2.14

Day's range

$2.01 - $2.14

52 week range

$1.38 - $3.47

Profile about CERS

CEO

William M. Greenman

Employees

275

Headquarters

Concord, CA

Exchange

NASDAQ Global Market

Shares outstanding

201954184

Issue type

Common Stock

CERS industries and sectors

Healthcare

Medical Equipment & Supplies

News on CERS

Cerus: 3 Key Takeaways for Long-Term Investors

Phase III REDeS study met primary efficacy and safety endpoints. Kit sales represented 90% of third-quarter fibrinogen complex product shipments.

news source

The Motley Fool • Nov 3, 2026

news preview

Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript

Cerus Corporation ( CERS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Timothy Lee - Head of Investor Relation Vivek Jayaraman - CEO, President & Director Kevin Green - VP of Finance & CFO Conference Call Participants Colin Clark - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Gabrielle Ingoglia - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Cerus Corp. Q3 2026 Earnings Conference Call.

news source

Seeking Alpha • Nov 3, 2026

news preview

Cerus' blood-safety system meets main goal in late-stage trial

Cerus' blood-safety system meets main goal in late-stage trial

news source

Reuters • Nov 2, 2026

news preview

Cerus Q3 Earnings Call Highlights

Cerus NASDAQ: CERS reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS study of pathogen-reduced red blood cells.

news source

MarketBeat • Nov 3, 2026

news preview

Cerus Corporation Announces Third Quarter 2026 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end,” said Vivek Jayaraman, Cerus's president and chief executive officer. “Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation.

news source

Business Wire • Nov 2, 2026

news preview

Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. “Over the past decade, pathogen reduction technology has become an integral component of the blood safety toolkit. The topline results from the RedeS study reinforce the potential to extend this established paradigm to red blood cell transfusions,” said Ross M. Fasano, MD, Professor of Pathology & Laboratory Medicine and Hematology at Emory.

news source

Business Wire • Nov 2, 2026

news preview

Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.

news source

Business Wire • Oct 19, 2026

news preview

Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from aroun.

news source

Business Wire • Oct 14, 2026

news preview

Cerus: This Blood-Safety Underdog Should Be Earning More Respect

Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product revenue grew 10%, operating expenses fell 7%, and adjusted EBITDA more than tripled year-over-year. Management raised full-year revenue guidance for the second time this year, now projecting $229–231 million, reflecting growing confidence in commercial momentum.

news source

Seeking Alpha • Aug 18, 2026

news preview

Cerus Q2 Earnings Call Highlights

Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.

news source

MarketBeat • Jul 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cerus Corporation

Open an M1 investment account to buy and sell Cerus Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CERS on M1